Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial-Reference-Cited by-同舟云学术

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

Published:2006-09-19 Issue:4 Volume:66 Page:498-505
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Kavanaugh A,Krueger G G,Beutler A,Guzzo C,Zhou B,Dooley L T,Mease P J,Gladman D D,de Vlam K,Geusens P P,Birbara C,Halter D G,Antoni C,

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy;Rheumatology and Therapy;2024-08-12

2. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis;The Journal of Rheumatology;2024-04-01

3. Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment;Immunotherapy;2024-02-06

4. Patients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort;Advances in Rheumatology;2024-01-02

5. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review;RMD Open;2024-01